Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer

A. Y.C. Chang, A. Solan, B. H. Kaplan, S. E. Vogl, F. J. Camacho, S. G. Taylor IV

Research output: Contribution to journalArticle


Twelve patients with recurrent and metastatic breast cancer were treated with a combination of adriamycin and amsacrine (m-AMSA) to evaluate its efficacy and toxicity. Adriamycin was given at 40 mg/m2 i.v. and m-AMSA at 50 mg/m2 i.v. every 3 weeks. No response was observed. One patient received an escalated m-AMSA dose at 70 mg/m2 and the same dose of adriamycin. She died of treatment-related leukopenia and infection. We conclude that the combination of adriamycin and amsacrine at the dose and schedule used in our trial has little antitumor effect in the treatment of advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)535-537
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number5
StatePublished - Jan 1 1988
Externally publishedYes


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this